News

RESEARCHER SPOTLIGHT Adam Green, MD

Monday, April 23, 2018

Dr. Adam Green joined the neuro-oncology group at Children’s Hospital Colorado in 2014. He has a dual role – caring for patients at Children’s Hospital Colorado in the pediatric neuro-oncology department and conducting research for The Morgan Adams Foundation Pediatric Brain Tumor Research Program. His goal is to develop better treatments, and ultimately a cure, for rare brain tumors that have low survival rates. Diffuse Intrinsic Pontine Glioma (DIPG), which has a 0% survival rate, is at the top of his list. The tumor is rare: about 200 patients, mostly between the ages of five and nine, are diagnosed each year in the U.S. The sole treatment option for DIPG is radiation, which only serves to slow the tumor’s progression, not stop it.
 
WHY STUDY DIPG?
I planned to become a pediatrician when I was in high school and I was a neurobiology major in college. I became interested in pediatric brain tumors in medical school and then specifically in DIPG because of a patient I treated during my first year of fellowship. It felt unacceptable to me that we still have a disease in our field for which we can offer patients and families no hope for cure, unlike every other cancer we treat. I felt compelled to try to change this through research.
 
RESEARCH FOCUS:
In my work on DIPG to this point, we have used cell culture and lab models of the disease, created directly from patient tumor samples, to identify new weaknesses in these tumors and try to exploit those weaknesses through new treatments. We have been able to bring two of these treatments into clinical trials.
 
GETTING CHEMO TO THE TUMOR:
One trial is designed to determine whether chemotherapy delivered orally or by IV can penetrate to DIPG tissue enough to have an effect. The trial arose from work conducted in our lab as part of The Morgan Adams Foundation Pediatric Brain Tumor Research Program and is currently expanding to other hospitals. The trial will help us decide whether we should continue to investigate new medicines delivered by these routes or focus on delivering chemotherapy directly to the tumor. I am confident we’ll be able to answer this question.
 
ONE TRIAL COMING UP:
Dr. Green and his colleagues will present findings from this clinical trial at the International Symposium on Pediatric Neuro-Oncology, taking place this July in Denver.

 


MAF Families and Supporters Invited to Attend ISPNO 2018 Family Day

Monday, April 16, 2018
On June 29th, The Morgan Adams Foundation and other organizations will host Family Day on the University of Colorado Anschutz Medical Campus in Denver.
 
ISPNO Family Day will include a full day of programs specifically created for families of Central Nervous System tumor patients and will cover a wide range of topics, including research updates, education issues, nutrition and wellness, caregiving, and creating a family’s “new normal.” A special, specific track for adolescents/young adults battling cancer will be offered, and there will also be a special breakout session for grieving families. The day’s sessions will be followed by a cocktail hour and dinner.
 
Family Day is free for our cancer families - however PLEASE DO REGISTER so we can have an accurate head count for lunch and snacks! We hope to see you there.
 
For additional information AND TO REGISTER, please visit ispno2018.com.

Denver to Host 18th International Symposium on Pediatric Neuro-Oncology

Monday, April 02, 2018

The 18th International Symposium on Pediatric Neuro-Oncology – a unique forum that brings together leading researchers, physicians, surgeons, nurses, and social workers to exchange information and results and collaborate – is coming to Denver this summer. ISPNO is the major global meeting of the international community of professionals involved in the scientific research, diagnosis, treatment, and rehabilitation of infants, children, and young people with central nervous system (CNS) tumors.

This is the first time the symposium will be held in the U.S. since 2008. Denver being named as a host site marks another recognition of the groundbreaking research being conducted at the University of Colorado and Children’s Hospital Colorado.

“The fact that this international, highly regarded conference is being held in Denver speaks directly to the leading edge research being conducted at Children’s Hospital Colorado, research that would not have been possible without The Morgan Adams Foundation,” said Nick Foreman, MD, ISPNO conference co-chair and Associate Chief of the Center for Cancer and Blood Disorders at Children’s Hospital Colorado. “The Symposium is critically important for researchers around the world. It provides a forum for the thoughtful exchange of information and many opportunities to further collaborative efforts, both of which will lead to more promising studies that we can use to help our patients.”

The Sympoisum will take place from June 30 to July 3 at the Hyatt Regency Hotel in downtown Denver. It will include plenary and poster sessions, keynote talks, and roundtable discussions about the latest research and clinical care of pediatric CNS tumors.

More than 1,500 pediatric neuro-oncology specialists from around the world will come to Denver to engage in dialogue regarding new treatments, innovative research, and advances in pediatric neuro-oncology. VOLUNTEERS NEEDED! Please email joan@morganadamsfoundation.org if you are able to help!
 
For more information, please visit ispno2018.com.

 

 


Newsletter March 2018

Saturday, March 31, 2018

Read our March 2018 Newsletter HERE.